Tag: lorlatinib
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD
Posted: June 24, 2020
An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients...
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD
Posted: April 16, 2020
After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life...
